Macrophage-mediated phagocytosis: treating solid tumours
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
List view / Grid view
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
Following Zymeworks’ presentation at AACR 2024, in this Q&A, Dr Nina Weisser explains how the next generation trispecific T cell engager platform with integrated CD28 costimulation is engineered to tackle solid tumours.
The FDA has cleared the Simcere's investigational new drug application for SIM0237, an anti-PD-L1/IL-15 bi-functional fusion protein, for the treatment of adult patients with advanced solid tumours.
The prodrug developed by researchers caused long-term remission in all murine models of high-risk or drug-resistant cancers with fewer side-effects than a comparable drug.
Researchers have reprogrammed CAR T cells to prevent them becoming exhausted after prolonged activity, presenting a possible new therapy for solid tumours.